US24661P8077
© BusinessWire
09.01.2026
DCTH
LISTED
NASDAQ
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
Preliminary Fourth Quarter and Full-Year 2025 Fi...
Themefolio
Profiler
Peergroup
© BusinessWire
31.12.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled “Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepa...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, title...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
20.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
18.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metas...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to six individuals whose employment com...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of long...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate in Upcoming Investor Conferences
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:
Craig-Hallum Alpha Select Conference on Tuesday, November 18, 2025, in New York, NY
Canaccord Genuity MedTech, Di...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
DCTH
LISTED
NASDAQ
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Results
Total revenue of $20.6 million, com...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Host Third Quarter 2025 Earnings Call
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025.
Conference Call Information
To participa...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance.
Preliminary Third Quarter Financial Results (unaudited)
Total...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical Cente...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
22.09.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Princi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2025
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose employment c...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate in Upcoming Investor Conferences
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:
Wells Fargo Healthcare Conference on Thursday, September 4, 2025, in Boston, MA
H.C. Wainwright 27th Annual Glo...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment fo...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at The InterContinental Boston in Boston, MA.
About Delcath Systems, In...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose employment c...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Host Second Quarter 2025 Earnings Call
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025.
Conference Call Information
To participate in...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
DCTH
LISTED
NASDAQ
Delcath Systems Issues Full Year 2025 Guidance
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access.
2025 Full Year Financia...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN.
About Delcath Systems, In...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
DCTH
LISTED
NASDAQ
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to eleven individuals whose employment...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
DCTH
LISTED
NASDAQ
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.
First Quarter 2025 Financial Results
Total revenue of $19.8 million, compare...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in c...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Host First Quarter 2025 Earnings Call
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025.
Conference Call Information
To participate in this...
Themefolio
Profiler
Peergroup
© BusinessWire
09.04.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the randomized cohort of the Company’s Phase 3 FOCUS study in Annals of Surgical Oncology. The study, titled “An Open-label, Randomized Study of Me...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons in Oncology Virtual Conference on April 7, 2025 at 10:00 a.m. ET. Investors interested in participating should contact their Canaccord...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to six individuals whose employment com...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
DCTH
LISTED
NASDAQ
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024.
Fourth Quarter and Full Year 2024 Financial Results...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 6, 2025, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2024.
Conference Call Information
To...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of metastatic uvea...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025 at The Cliff Lodge in Snowbird, UT.
A...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
DCTH
LISTED
NASDAQ
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024.
Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unau...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
DCTH
LISTED
NASDAQ
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual w...
Themefolio
Profiler
Peergroup
© BusinessWire
30.12.2024
DCTH
LISTED
NASDAQ
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
DCTH
LISTED
NASDAQ
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
News Preview
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in c...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
DCTH
LISTED
NASDAQ
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024.
Third Quarter and Recent Business Highlights
Total third quarter r...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
DCTH
LISTED
NASDAQ
Delcath Systems to Participate in Upcoming Investor Conferences
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences:
Stephens Biotechnology Virtual Fireside Chats
Date: Wednesday, November 13, 2024
Fireside Chat Time: 9:30 a...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2024
DCTH
LISTED
NASDAQ
Delcath Systems to Host Third Quarter 2024 Earnings Call
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024.
Conference Call Information
To participate...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
DCTH
LISTED
NASDAQ
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the com...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
DCTH
LISTED
NASDAQ
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted three equity awards, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of three indiv...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
DCTH
LISTED
NASDAQ
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System (HDS)) in patients with metastatic uveal melanoma (mUM). The data were presented by Dr. M...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, entitled “Melanoma-specific survival of patients...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
DCTH
LISTED
NASDAQ
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 11:00 a.m. Eastern Time at the Lott...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by independent investigators in the Annals of Surgical Oncology. The study, titled “Hepatic and Overall Progression-Fre...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal o...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
DCTH
LISTED
NASDAQ
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it will present data from its FOCUS Phase 3 study at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, which convenes from September...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
DCTH
LISTED
NASDAQ
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted one equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual...
Themefolio
Profiler
Peergroup
© Newsfile
28.09.2020
DCTH
LISTED
NASDAQ
Encode Ideas, L.P. to Host Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System's Phase 3 FOCUS Study
News Preview
Dover, Delaware--(Newsfile Corp. - September 28, 2020) - Encode Ideas, L.P. announces they will be hosting a conference call with Dr. Jonathan Zager, surgical oncologist at Moffitt Cancer Center and the principal investigator for the Phase 3 FOCUS study, on Wednesday, September 30 at 3:00 pm Eastern Time. The purpose of the call will be to discuss...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
DCTH
LISTED
NASDAQ
Encode Ideas, L.P. Announces the Initiation of Research Coverage on Delcath Systems, Inc.
News Preview
Dover, Delaware--(Newsfile Corp. - May 19, 2020) - Encode Ideas, L.P. Initiates Research on Delcath Systems, Inc (NASDAQ: DCTH). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas is initiating coverage on Delcath Systems (NASDAQ: DCTH) as a high conviction investment id...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
